<DOC>
	<DOC>NCT00459004</DOC>
	<brief_summary>The primary objective is to verify the dose-response relationship of rimonabant on body weight change. The secondary objectives are to compare the effect of 3 doses of SR141716 to placebo, on body weight loss and on secondary criteria associated with comorbidities, and to evaluate the safety and the pharmacokinetics of SR141716.</brief_summary>
	<brief_title>Japanese Dose-Response Study of Rimonabant in Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Body Mass Index ≥25 kg/m² Viceral Fat Area ≥ 100 cm² Diet therapy for more than 8 weeks before start of the placebo observation period Stable weight (variation &lt; ±3kg within 8 weeks before start of observation period) At least 2 criteria of the following 3 comorbidities: Impaired Glucose Tolerance or Type 2 diabetes, Dyslipidemia (hypertriglyceridemia and/or low HDLchoresterol), Hypertension</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>weight loss</keyword>
</DOC>